WO2022231320A1 - Anticorps se liant de manière spécifique à la protéine s de sars-cov-2 ou à un fragment de liaison à l'antigène de celle-ci, et ses utilisations - Google Patents

Anticorps se liant de manière spécifique à la protéine s de sars-cov-2 ou à un fragment de liaison à l'antigène de celle-ci, et ses utilisations Download PDF

Info

Publication number
WO2022231320A1
WO2022231320A1 PCT/KR2022/006054 KR2022006054W WO2022231320A1 WO 2022231320 A1 WO2022231320 A1 WO 2022231320A1 KR 2022006054 W KR2022006054 W KR 2022006054W WO 2022231320 A1 WO2022231320 A1 WO 2022231320A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
antigen
cov
sars
Prior art date
Application number
PCT/KR2022/006054
Other languages
English (en)
Korean (ko)
Inventor
이석묵
김지웅
허균
조예빈
김현정
최혜림
양하림
신하경
Original Assignee
국민대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020210054596A external-priority patent/KR20220147766A/ko
Priority claimed from KR1020210054606A external-priority patent/KR20220147769A/ko
Priority claimed from KR1020210054590A external-priority patent/KR20220147765A/ko
Application filed by 국민대학교산학협력단 filed Critical 국민대학교산학협력단
Publication of WO2022231320A1 publication Critical patent/WO2022231320A1/fr
Priority to US18/383,595 priority Critical patent/US20240043508A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Definitions

  • the present invention was made by the project number 1711120289 under the support of the Ministry of Science and ICT of the Republic of Korea, and the research management institution for the above project is the National Research Foundation of Korea, the research project name is "Bio/Medical Technology Development Project”, and the research project name is "SARS-CoV2" Development of new dual antibody clinical candidates for target neutralization", the project execution institution is Kookmin University Industry-University Cooperation Foundation, and the research period is 2020.07.01-2021.12.31.
  • the present invention relates to antibodies or antigen-binding fragments thereof that specifically bind to SARS-CoV-2 S protein, and uses thereof. More specifically, it relates to an anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof, and a use for diagnosing or treating SARS-CoV-2 infection using the same.
  • S protein is a key marker molecule that is located on the surface of SARS-CoV-2 and binds to the receptor angiotensin-converting enzyme 2 (ACE2) on the host cell surface to induce infection. Therefore, the receptor binding domain of spike protein (hereinafter referred to as S-RBD) is a key target in the development of therapeutic agents that prevent infection by SARS-CoV-2.
  • Antibody therapeutics are recognized for their efficacy due to their high affinity and specificity for their target.
  • the present inventors made intensive research efforts to develop a pharmaceutical composition for the prevention or treatment of COVID-19 infectious disease.
  • novel anti-SARS-CoV-2 S protein antibodies or antigen-binding fragments thereof were developed, and it was confirmed that these antibodies or antigen-binding fragments exhibit high affinity for S protein, and completed the present invention.
  • an object of the present invention to provide an antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 S protein.
  • Another object of the present invention relates to a pharmaceutical composition for preventing or treating SARS-CoV-2 infection, comprising the antibody or antigen-binding fragment thereof, and a pharmaceutically acceptable carrier.
  • another object of the present invention is a composition or kit for detecting SARS-CoV-2 virus comprising the antibody or antigen-binding fragment thereof; Or to provide a composition or kit for diagnosing COVID-19 infection.
  • the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to SARS-CoV-2 S protein, selected from:
  • a heavy chain variable region comprising a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 2, and a CDR-H3 of SEQ ID NO: 3; and an antibody or antigen-binding fragment thereof comprising a light chain variable region of CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6;
  • a heavy chain variable region comprising a CDR-H1 of SEQ ID NO: 10, a CDR-H2 of SEQ ID NO: 11, and a CDR-H3 of SEQ ID NO: 12; and an antibody or antigen-binding fragment thereof comprising a light chain variable region of CDR-L1 of SEQ ID NO: 13, CDR-L2 of SEQ ID NO: 14, and CDR-L3 of SEQ ID NO: 15;
  • a heavy chain variable region comprising CDR-H1 of SEQ ID NO: 28, CDR-H2 of SEQ ID NO: 29, and CDR-H3 of SEQ ID NO: 30; and an antibody or antigen-binding fragment thereof comprising a light chain variable region of CDR-L1 of SEQ ID NO: 31, CDR-L2 of SEQ ID NO: 32, and CDR-L3 of SEQ ID NO: 33; and
  • a heavy chain variable region comprising a CDR-H1 of SEQ ID NO: 37, a CDR-H2 of SEQ ID NO: 38, and a CDR-H3 of SEQ ID NO: 39; and a light chain variable region of CDR-L1 of SEQ ID NO: 40, CDR-L2 of SEQ ID NO: 41, and CDR-L3 of SEQ ID NO: 42.
  • the antibodies or antigen-binding fragments thereof of (i) to (v) are derived from the clones RG6, RB4, RB6, RD3, and RD10 selected in Examples of the present invention, respectively.
  • (i) comprises a heavy chain variable region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8; wherein (ii) comprises a heavy chain variable region of SEQ ID NO: 16 and a light chain variable region of SEQ ID NO: 17; (iii) comprises a heavy chain variable region of SEQ ID NO: 25 and a light chain variable region of SEQ ID NO: 26; The (iv) comprises a heavy chain variable region of SEQ ID NO: 34 and a light chain variable region of SEQ ID NO: 35; The (v) includes, but is not limited to, the heavy chain variable region of SEQ ID NO: 43 and the light chain variable region of SEQ ID NO: 44.
  • (i) comprises the amino acid sequence of SEQ ID NO: 9
  • (ii) comprises the amino acid sequence of SEQ ID NO: 18, and (iii) comprises the amino acid sequence of SEQ ID NO: 27 Including, wherein (iv) includes the amino acid sequence of SEQ ID NO: 36, and (v) includes the amino acid sequence of SEQ ID NO: 45, but is not limited thereto.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention binds to a receptor binding domain (RBD) of SARS-CoV-2 S protein (spike protein).
  • RBD receptor binding domain
  • the RBD of the SARS-CoV-2 S protein comprises the amino acid sequence of SEQ ID NO: 51.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention inhibits the binding of SARS-CoV-2 S protein to RBD and human angiotensin converting enzyme 2 (ACE2). do.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment of the present invention binds to the S1 domain of SARS-CoV-2 S protein.
  • the S1 domain of the SARS-CoV-2 S protein comprises the amino acid sequence of SEQ ID NO: 52.
  • the S2 domain of the SARS-CoV-2 S protein comprises the amino acid sequence of SEQ ID NO: 53.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment of the present invention binds to a full-length spike protein of SARS-CoV-2 S protein.
  • the full-length spike protein of SARS-CoV-2 comprises the amino acid sequence of SEQ ID NO: 54.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment of the present invention specifically binds to a mutant virus in which the S protein of SARS-CoV-2 is mutated.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment specifically binds to a mutant virus in which the RBD region of the S protein of SARS-CoV-2 is mutated.
  • the mutant virus in which the RBD region of the S protein of SARS-CoV-2 to which the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment specifically binds is generated, In RBD, V431A mutation at amino acid position 431, F342L mutation at amino acid position 342, V367F mutation at amino acid position 367, R408I mutation at amino acid position 408, A435S mutation at amino acid position 435, W436R mutation at amino acid position 436, It is a mutant virus in which G476S mutation at amino acid position 476, V483A mutation at amino acid position 483, and N354D/D364Y mutation at amino acid positions 354 and 364 occur, but is not limited thereto.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof specifically binds to a mutant virus mutated in a region other than the S protein of SARS-CoV-2.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof specifically binds to the S protein of SARS-CoV.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment specifically binds to the RBD region of the S protein of SARS-CoV.
  • the RBD region of the S protein includes the amino acid sequence of SEQ ID NO: 55, but is not limited thereto.
  • Antibodies of the present invention can be generated using various phage display methods known in the art [Brinkman et al., 1995, J. Immunol. Methods, 182:41-50]; [Ames et al., 1995, J. Immunol. Methods, 184, 177-186]; [Kettleborough et al. 1994, Eur. J. Immunol, 24, 952-958]; [Persic et al., 1997, Gene, 187, 9-18]; and Burton et al., 1994, Adv.
  • antibody refers to a specific antibody against SARS-CoV S protein, and includes not only a complete antibody form but also an antigen binding fragment of an antibody molecule.
  • a complete antibody has a structure having two full-length light chains and two full-length heavy chains, each light chain linked to a heavy chain by a disulfide bond.
  • the heavy chain constant region has gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and epsilon ( ⁇ ) types and subclasses gamma 1 ( ⁇ 1), gamma 2 ( ⁇ 2), gamma 3 ( ⁇ 3). ), gamma 4 ( ⁇ 4), alpha 1 ( ⁇ 1) and alpha 2 ( ⁇ 2).
  • the constant region of the light chain has kappa and lambda types (Cellular and Molecular Immunology, Wonsiewicz, M. J., Ed., Chapter 45, pp. 41-50, W. B. Saunders Co. Philadelphia, PA (1991); Nisonoff, A., Introduction to Molecular Immunology, 2nd Ed., Chapter 4, pp. 45-65, sinauer Associates, Inc., Sunderland, MA (1984)).
  • the term "antigen-binding fragment” refers to a fragment having an antigen-binding function, Fab, F(ab'), F(ab') 2 , chemically linked F(ab') 2 and Fv, etc. includes Among the antibody fragments, Fab has a structure having variable regions of light and heavy chains, a constant region of a light chain and a first constant region (CH1) of a heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region comprising one or more cysteine residues at the C-terminus of the heavy chain CH1 domain.
  • the F(ab') 2 antibody is produced by forming a disulfide bond with a cysteine residue in the hinge region of Fab'.
  • Fv is a minimal antibody fragment having only a heavy chain variable region and a light chain variable region, and recombinant technology for generating Fv fragments is described in PCT International Patent Application Publications WO 88/10649, WO 88/106630, WO 88/07085, WO 88/07086 and WO 88/09344.
  • a double-chain Fv two-chain Fv
  • the heavy chain variable region and the light chain variable region are connected by a non-covalent bond
  • single-chain Fv single-chain Fv
  • the heavy chain variable region and the single chain variable region are generally shared through a peptide linker. Since they are linked by a bond or are linked directly at the C-terminus, they can form a dimer-like structure like a double-stranded Fv.
  • Such antibody fragments can be obtained using proteolytic enzymes (e.g., papain-restricted digestion of the whole antibody yields Fab and pepsin digestion yields F(ab') 2 fragments), or It can be produced through genetic recombination technology.
  • the antibody is specifically in the form of an scFv or a complete antibody.
  • the heavy chain constant region may be selected from any one of gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) or epsilon ( ⁇ ) isotypes.
  • the constant regions are gamma 1 (IgG1), gamma 2 (IgG2), gamma 3 (IgG3) and gamma 4 (IgG4), most specifically gamma 4 (IgG4) isotypes.
  • the light chain constant region may be kappa or lambda type, preferably kappa type.
  • the antibody of the present invention may be in the form of scFv or IgG4 having a kappa light chain and a gamma 4 heavy chain.
  • the specific antibody of the present invention may be in the form of scFv or IgG1 having a kappa light chain and a gamma 1 heavy chain.
  • the term “heavy chain” refers to a full-length heavy chain comprising a variable region domain VH comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen and three constant region domains CH1, CH2 and CH3, and a full-length heavy chain thereof It means all fragments.
  • the term “light chain” refers to both a full-length light chain including a variable region domain VL and a constant region domain CL including an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen and a fragment thereof. do.
  • CDR complementarity determining region
  • the antibody or antigen-binding fragment thereof includes a full-length or pristine polyclonal or monoclonal antibody, as well as antigen-binding fragments thereof (eg, Fab, Fab', F(ab')2, Fab3).
  • fusion proteins comprising one or more antibody portions, human antibodies, humanized antibodies, chimeric antibodies, minibodies, diabodies, triabodies, tetrabodies, linear antibodies, single chain antibodies (scFv) , scFv-Fc, bispecific antibodies, multispecific antibodies, glycosylation variants of antibodies, amino acid sequence variants of antibodies and covalent modifications of other modified configurations of immunoglobulin molecules comprising antigen recognition sites of the required specificity. including antibodies.
  • modified antibodies and antigen-binding fragments thereof include Nanobodies, AlbudAbs, DARTs (dual affinity re-targeting), BiTEs (bispecific T-cell engager), TandAbs (tandem diabodies), DAFs (dual acting Fab), two- These include in-one antibodies, SMIPs (small modular immunopharmaceuticals), FynomAbs (fynomers fused to antibodies), DVD-Igs (dual variable domain immunoglobulin), CovX-bodies (peptide modified antibodies), duobodies and triomAbs.
  • the list of such antibodies and antigen-binding fragments thereof is not limited above.
  • FR refers to variable domain residues other than hypervariable region (HVR) residues.
  • the FRs of a variable domain generally consist of the four FR domains FR1, FR2, FR3 and FR4.
  • HVR and FR sequences generally appear in VH (or VL/Vk) in the following order:
  • FRL1 Framework region 1 of Light chain
  • CDRL1 complementarity determining region 1 of Light chain
  • variable region refers to a domain of an antibody heavy or light chain that is involved in binding an antibody to an antigen.
  • the variable domains of the heavy and light chains of native antibodies (VH and VL, respectively) generally have a similar structure, each domain comprising four conserved framework regions (FR) and three hypervariable regions (HVR). ) is included.
  • FR conserved framework regions
  • HVR hypervariable regions
  • a single VH or VL domain may be sufficient to confer antigen-binding specificity.
  • antibodies that bind to a specific antigen can be isolated using the VH or VL domains from antibodies that bind antigen and screen a library of complementary VL or VH domains, respectively.
  • the term “specifically binds” or the like means that an antibody or antigen-binding fragment thereof, or other construct such as an scFv, forms a complex with an antigen that is relatively stable under physiological conditions. Specific binding is at least about 1 x 10 -6 M or less (eg, 9 x 10 -7 M, 8 x 10 -7 M, 7 x 10 -7 M, 6 x 10 -7 M, 5 x 10 -7 M , 4 x 10 -7 M, 3 x 10 -7 M, 2 x 10 -7 M, or 1 x 10 -7 M), preferably 1 x 10 -7 M or less (eg, 9 x 10 -8 M , 8 x 10 -8 M, 7 x 10 -8 M, 6 x 10 -8 M, 5 x 10 -8 M, 4 x 10 -8 M, 3 x 10 -8 M, 2 x 10 -8 M, or 1 x 10 -8 M), more preferably 1 x 10 -8 M or less (eg, 9 x
  • affinity refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (eg, an antibody) and its binding partner (eg, an antigen).
  • binding affinity refers to an intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (eg, antibody and antigen). indicates The affinity of a molecule Y and its partner Y can generally be expressed as the dissociation constant (Kd). Affinity can be measured by conventional methods known in the art, including those described herein.
  • human antibody refers to the amino acid sequence of an antibody produced by a human or human cell, or an antibody derived from a non-human source using human antibody repertoires or other human antibody coding sequences. It has the corresponding amino acid sequence. This definition of a human antibody excludes a humanized antibody comprising non-human antigen-binding residues.
  • chimeric antibody means that a portion of the heavy and/or light chain is derived from a particular source or species, and the remainder of the heavy and/or light chain is derived from a different source or species. means antibodies.
  • humanized antibody refers to a chimeric immunoglobulin containing minimal sequence derived from the non-human immunoglobulin of a non-human (eg, mouse) antibody, an immunoglobulin chain or fragment thereof (eg, Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequence of an antibody).
  • humanized antibodies contain CDRs of a non-human species (donor antibody), such as mouse, rat or rabbit, in which residues of the complementarity-determining region (CDR) of the recipient have the desired specificity, affinity and capacity.
  • donor antibody such as mouse, rat or rabbit
  • human immunoglobulin (recipient antibody) replaced by a residue of
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • a humanized antibody may comprise residues that are not found either in the recipient antibody or in the imported CDR or framework sequences. Such modifications are made to further improve and optimize antibody performance.
  • the humanized antibody will comprise at least one, and typically two, substantially all variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of a non-human immunoglobulin, All or substantially all of the FR region has the sequence of the FR region of a human immunoglobulin.
  • the humanized antibody comprises at least a portion of an immunoglobulin constant region (Fc region) to substantially a human immunoglobulin constant region (Fc region) sequence.
  • Such variants are said to have "substantial similarity", wherein the two peptide sequences have at least about 90% sequence identity, more preferably at least about means sharing 95%, 98% or 99% sequence identity.
  • residue positions that are not identical differ by conservative amino acid substitutions.
  • a "conservative amino acid substitution” is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (eg charge or hydrophobicity).
  • conservative amino acid substitutions do not substantially change the functionality of the protein.
  • the percent or degree of similarity may be up-regulated to correct for the conservative nature of the substitutions.
  • amino acid variations are made based on the relative similarity of amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, and the like.
  • amino acid side chain substituents such as hydrophobicity, hydrophilicity, charge, size, and the like.
  • arginine, lysine and histidine are all positively charged residues; alanine, glycine and serine have similar sizes; It can be seen that phenylalanine, tryptophan and tyrosine have similar shapes. Therefore, based on these considerations, arginine, lysine and histidine; alanine, glycine and serine; And phenylalanine, tryptophan and tyrosine can be said to be biologically functional equivalents.
  • the hydropathic idex of the amino acid may be considered.
  • Each amino acid is assigned a hydrophobicity index according to its hydrophobicity and charge: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cysteine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
  • the hydrophobic amino acid index is very important in conferring an interactive biological function of a protein. It is a known fact that amino acids having a similar hydrophobicity index must be substituted to retain similar biological activity. When introducing a mutation with reference to the hydrophobicity index, the substitution is made between amino acids exhibiting a difference in the hydrophobicity index within preferably ⁇ 2, more preferably within ⁇ 1, and even more preferably within ⁇ 0.5.
  • the substitution is made between amino acids exhibiting a difference in the hydrophilicity value within preferably ⁇ 2, more preferably within ⁇ 1, and even more preferably within ⁇ 0.5.
  • Amino acid exchanges in proteins that do not entirely alter the activity of the molecule are known in the art (H. Neurath, R.L. Hill, The Proteins, Academic Press, New York, 1979).
  • the most common exchanges are amino acid residues Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thy/Phe, Ala/ Exchange between Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly.
  • the antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 S protein of the present invention is expressed as RG6, RB4, RB6, RD3, RD10.
  • the antibody or antigen-binding fragment has a dissociation constant K D value of the S protein for RBD of 7.2x10 -10 M or less.
  • the antibody or antigen-binding fragment has a dissociation constant K D value of the S protein for the S1 antigen of 3.2x10 -9 M or less.
  • the antibody or antigen-binding fragment thereof RG6, RB4, RB6, RD3, RD10 that specifically binds to the SARS-CoV-2 S protein of the present invention is the above-mentioned SARS-CoV-2 It specifically binds to the RBD antigen of the S protein as well as the RBD of the S protein of SARS-CoV.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention is an anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof comprising a small change to the above-described amino acid sequence, that is, a modification that has little effect on the tertiary structure and function of the antibody.
  • SARS-CoV-2 S protein antibody or antigen-binding fragment thereof Therefore, in some embodiments, even if they do not match the above-described sequences, they may have at least 100%, 93%, 95%, 96%, 97%, or 98% or more similarity.
  • the anti-SARS-CoV-2 S antibody or antigen-binding fragment thereof of the present invention is a monoclonal antibody comprising a heavy chain variable region and a light chain variable region comprising the CDRs of the above sequences, dual Specific antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, single chain antibodies (scFv), Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFV) and anti-idiotypes ( anti-Id) antibodies, and epitope-binding fragments thereof.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention is an anti-SARS-CoV-2 S protein scFv.
  • the heavy chain variable region and the light chain variable region included in the antibody or antigen-binding fragment thereof are (Gly-Ser)n, (Gly 2 -Ser)n, (Gly 3 -Ser)n or ( It is linked by a linker such as Gly 4 -Ser)n.
  • n is an integer of 1 to 6, specifically 3 to 4, but is not limited thereto.
  • the light chain variable region and heavy chain variable region of the scFv may exist in, for example, the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.
  • the present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding the above-described anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof.
  • nucleic acid molecule has a meaning comprehensively including DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic structural units in nucleic acid molecules, include natural nucleotides as well as analogs in which sugar or base sites are modified. (analogue) (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews , 90:543-584 (1990)).
  • nucleotide sequence encoding the antibody or antigen-binding fragment thereof of the present invention is sufficient to be a nucleotide sequence encoding an amino acid sequence constituting the antibody or antigen-binding fragment thereof, and is not limited to any specific nucleotide sequence. .
  • nucleotide sequence is a functionally equivalent codon or codon encoding the same amino acid (e.g., due to codon degeneracy, there are six codons for arginine or serine), or a codon encoding a biologically equivalent amino acid It contains a nucleotide sequence comprising a.
  • nucleic acid molecule of the present invention encoding the amino acid sequence constituting the antibody or antigen-binding fragment thereof also includes a sequence exhibiting substantial identity thereto.
  • the substantial identity is at least when the sequence of the present invention and any other sequences are aligned to correspond as much as possible, and the aligned sequence is analyzed using an algorithm commonly used in the art.
  • At least 60% homology such as 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, or 69%), more specifically at least 70% homology (such as 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, or 79%), even more specifically at least 80% homology (such as 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%), even more specifically at least 90% homology (such as 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%), most specifically 95% or greater homology (eg, 95%, 96%, 97%, 98%, or 99%). All integers greater than or equal to 60% and less than or equal to 100%, and prime numbers therebetween, are included within the scope of the present invention with respect to % homology.
  • NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403-10(1990)) is accessible from the National Center for Biological Information (NBCI), etc. It can be used in conjunction with sequencing programs such as blastx, tblastn and tblastx. BLAST can be accessed through the BLAST page of the ncbi website. A method for comparing sequence homology using this program can be found on the BLAST help page of the ncbi website.
  • BLAST Basic Local Alignment Search Tool
  • a polypeptide constituting the heavy chain CDR, light chain CDR, heavy chain variable region, light chain variable region, heavy chain, or light chain of the SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention and the nucleotide sequence encoding it are listed in the appended sequence listing herein.
  • the present invention provides a recombinant vector comprising a nucleic acid molecule encoding the above-described anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof.
  • vector refers to a means for expressing a target gene in a host cell, including a plasmid vector; cozmid vector; and viral vectors such as bacteriophage vectors, adenoviral vectors, retroviral vectors and adeno-associated viral vectors, and the like.
  • a nucleic acid molecule encoding a heavy chain variable region and a nucleic acid molecule encoding a light chain variable region are operatively linked to a promoter.
  • operatively linked refers to a functional linkage between a nucleic acid expression control sequence (eg, a promoter, signal sequence, or an array of transcriptional regulator binding sites) and another nucleic acid sequence, , whereby the regulatory sequence regulates the transcription and/or translation of the other nucleic acid sequence.
  • a nucleic acid expression control sequence eg, a promoter, signal sequence, or an array of transcriptional regulator binding sites
  • the recombinant vector system of the present invention can be constructed through various methods known in the art, and specific methods thereof are disclosed in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001). , this document is incorporated herein by reference.
  • Vectors of the invention can typically be constructed as vectors for cloning or as vectors for expression.
  • the vector of the present invention can be constructed using a prokaryotic cell or a eukaryotic cell as a host.
  • a promoter derived from the genome of a mammalian cell eg, a metallotionine promoter, a beta-actin promoter, a human hegglobin promoter and human muscle creatine promoter
  • promoters derived from mammalian viruses eg, adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter
  • the LTR promoter of HIV, the promoter of Moloney virus, the promoter of Epstein Barr virus (EBV), and the promoter of Loose sarcoma virus (RSV) can be used, and generally have a polyadenylation sequence as a transcription termination sequence.
  • the vector of the present invention may be fused with other sequences to facilitate purification of the antibody expressed therefrom.
  • the sequence to be fused includes, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA) and 6x His (hexahistidine; Quiagen, USA).
  • the protein expressed by the vector of the present invention is an antibody
  • the expressed antibody can be easily purified through a protein A column or the like without an additional sequence for purification.
  • the expression vector of the present invention includes an antibiotic resistance gene commonly used in the art as a selection marker, for example, ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neo There is a gene for resistance to mycin and tetracycline.
  • the vector may additionally carry genes encoding reporter molecules (eg, luciferase and -glucuronidase).
  • reporter molecules eg, luciferase and -glucuronidase
  • the expression vector is a vector into which a nucleic acid molecule encoding the anti-SARS-CoV-2 S antibody or antigen-binding fragment thereof is inserted, and operably binds to a nucleotide sequence of the nucleic acid molecule. It is a recombinant vector for host cell expression that is operatively linked and includes a promoter that forms an RNA molecule in a host cell and a poly A signal sequence that acts in the host cell to cause polyadenylation of the 3'-end of the RNA molecule.
  • the present invention provides an isolated host cell transformed with a recombinant vector.
  • a host cell capable of stably and continuously cloning and expressing the vector of the present invention is known in the art and any host cell can be used.
  • suitable eukaryotic host cells of the vector include yeast (Saccharomyce cerevisiae), insect cells. , monkey kidney cells (COS7), NSO cells, SP2/0, Chinese hamster ovary (CHO) cells, W138, baby hamster kidney (BHK) cells, MDCK, myeloma cell line , HuT 78 cells and HEK-293 cells.
  • transformed As used herein, the terms “transformed”, “transduced” or “transfected” refer to the process by which an exogenous nucleic acid is transferred or introduced into a host cell.
  • An "infected” cell is a cell that has been transformed, transduced, or transfected with an exogenous nucleic acid, including the cell and progeny cells resulting from passage thereof.
  • Methods for delivering the vector of the present invention into a host cell include, when the host cell is a eukaryotic cell, a microinjection method (Capecchi, M.R., Cell, 22:479 (1980)), a calcium phosphate precipitation method (Graham, F.L. et al. , Virology, 52:456 (1973)), electroporation (Neumann, E. et al., EMBO J., 1:841 (1982)), liposome-mediated transfection (Wong, T.K. et al., Gene) , 10:87 (1980)), DEAE-dextran treatment (Gopal, Mol.
  • the recombinant vector injected into the host cell can express the above-mentioned antibody or polypeptide complex recombined in the host cell, and in this case, a large amount of the antibody or polypeptide complex is obtained.
  • the expression vector includes the lac promoter
  • the host cell may be treated with IPTG to induce gene expression.
  • the culture is usually carried out under aerobic conditions, such as by shaking culture or rotation on a rotary machine.
  • the culture temperature is preferably in the range of 10 to 40°C, and the culture time is generally 5 hours to 7 days.
  • the pH of the medium is preferably maintained in the range of 3.0 to 9.0 during culture.
  • the pH of the medium can be adjusted with inorganic or organic acids, alkaline solutions, urea, calcium carbonate, ammonia, and the like.
  • antibiotics such as ampicillin, streptomycin, chloramphenicol, kanamycin and tetracycline may be added for maintenance and expression of the recombinant vector.
  • a suitable inducer may be added to the medium.
  • a lac promoter IPTG (isopropyl-beta-D-thiogalactopyranoside) may be added, and if the expression vector contains a trp promoter, indoleacrylic acid may be added to the medium.
  • the present invention provides a polypeptide complex in which the aforementioned i) anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof and ii) an additional polypeptide are linked.
  • additional polypeptide is an antibody or antigen-binding fragment as described above, or a “target-binding polypeptide” or “polypeptide of a target” that is not an antibody or antigen-binding fragment.
  • an antibody or antigen-binding fragment as an additional polypeptide constituting the polypeptide complex of the present invention comprises i) an anti-SARS-CoV-2 S protein antibody or antigen-binding thereof It may specifically bind to the same or a different antigen as the fragment.
  • the i) anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof targets the same antigen as the additional polypeptide of ii), it is preferable to have different epitopes from each other.
  • target binding polypeptide refers to a non-immunoglobulin polypeptide molecule that has binding affinity for a target antigen or hapten, such as an antibody, but is structurally unrelated to the antibody.
  • the target-binding polypeptide is also called an antibody-like molecule or antibody mimetics, and generally has a molecular weight of 3-20 kDa, unlike an antibody having a molecular weight of about 150 kDa.
  • the target-binding polypeptide is an affibody derived from the Z-domain of protein A, affilin derived from gamma-B crystallin or ubiquitin, and an affimer derived from cystatin.
  • target-binding polypeptide may be engineered to have binding affinity for any target antigen or hapten through various screening methods known in the art, such as phage display and ribosome display.
  • the target-binding polypeptide may be a polypeptide derived from a host cell that binds to SARS-CoV-2 corresponding to the target of the present invention.
  • the target binding polypeptide is an ACE2 receptor of a host cell
  • the ACE2 receptor linked to the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof binds to SARS-CoV-2 and through this, SARS-CoV-2 By neutralizing SARS-CoV-2, it is possible to prevent entry into host cells.
  • target polypeptide refers to a polypeptide derived from SARS-CoV-2 corresponding to the target of the present invention, which binds to other polypeptides constituting SARS-CoV-2. This target polypeptide binds to other polypeptides constituting SARS-CoV-2, thereby preventing the invasion of SARS-CoV-2 into host cells.
  • the target polypeptide may be a polypeptide used when SARS-CoV-2 invades a host cell, and specifically may be a polypeptide constituting a Spike protein, but is not limited thereto.
  • the polypeptide complex according to one embodiment of the present invention is in a multimeric form in which each antibody or antigen-binding fragment and a monomer of the polypeptide are linked.
  • the polypeptide complex of the present invention is covalently linked to each other, and according to one embodiment of the present invention, the polypeptide complex may be implemented in the form of a fused protein or a conjugate.
  • the polypeptide complex may be implemented in the form of a fused protein or a conjugate.
  • the antibody or antigen-binding fragment thereof may be prepared by chemical conjugation (known as organic chemistry methods) or other means (eg, expressing the complex as a fusion protein, directly or indirectly through a linker (eg, an amino acid linker)).
  • linker eg, an amino acid linker
  • each polypeptide monomer constituting the polypeptide complex is connected by at least one linker.
  • the linker may consist of an amino acid sequence represented by the general formula (GnSm)p or (SmGn)p:
  • n, m and p are independently,
  • n is an integer from 1 to 7;
  • n is an integer from 0 to 7;
  • n and m are integer less than or equal to 8.
  • p is an integer from 1 to 7.
  • the linker is (GGGGS) 3 .
  • the linker is GGGGS.
  • the linker is VDGS.
  • the linker is ASGS.
  • the polypeptide complex may be a multi-antibody with two or more targets.
  • the polypeptide complex of the present invention may include two or more antibodies or antigen-binding fragments thereof selected from the following (i) to (v), but is not limited thereto:
  • a heavy chain variable region comprising a CDR-H1 of SEQ ID NO: 1, a CDR-H2 of SEQ ID NO: 2, and a CDR-H3 of SEQ ID NO: 3; And an antibody or antigen binding thereof that specifically binds to SARS-CoV-2 S protein comprising the light chain variable regions of CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6 snippet;
  • a heavy chain variable region comprising a CDR-H1 of SEQ ID NO: 10, a CDR-H2 of SEQ ID NO: 11, and a CDR-H3 of SEQ ID NO: 12; And an antibody or antigen binding thereof that specifically binds to SARS-CoV-2 S protein comprising the light chain variable regions of CDR-L1 of SEQ ID NO: 13, CDR-L2 of SEQ ID NO: 14, and CDR-L3 of SEQ ID NO: 15 snippet;
  • a heavy chain variable region comprising a CDR-H1 of SEQ ID NO: 37, a CDR-H2 of SEQ ID NO: 38, and a CDR-H3 of SEQ ID NO: 39; And an antibody or antigen binding thereof that specifically binds to SARS-CoV-2 S protein comprising a light chain variable region of CDR-L1 of SEQ ID NO: 40, CDR-L2 of SEQ ID NO: 41, and CDR-L3 of SEQ ID NO: 42 snippet.
  • the polypeptide complex comprising two or more antibodies or antigen-binding fragments thereof selected from (i) to (v) is selected from two or more antibodies selected from (i) to (v) or its
  • the antigen-binding fragment may be prepared as a fusion protein by means of an amino acid linker or in the form of a conjugate by chemical conjugation.
  • the present invention provides a nucleic acid molecule encoding the polypeptide complex.
  • the nucleic acid molecule according to an aspect of the present invention is a nucleic acid molecule comprising a nucleotide sequence encoding an anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof according to an aspect of the present invention as described above. All are equally applied, and description thereof is omitted to avoid excessive complexity of the present specification.
  • the present invention provides SARS-CoV- comprising an antibody or antigen-binding fragment thereof that specifically binds to the above-described SARS-CoV-2 S protein, and a pharmaceutically acceptable carrier. 2 It provides a pharmaceutical composition for preventing or treating an infection.
  • the SARS-CoV-2 causing SARS-CoV-2 infection is a mutant virus in which the S protein thereof is mutated.
  • the mutant virus is a mutant virus in which the RBD region of the S protein is mutated.
  • the mutant virus in which the RBD region of the S protein is mutated is V431A mutation at amino acid position 431, F342L mutation at amino acid position 342, V367F mutation at amino acid position 367, 408 of the RBD.
  • R408I mutation at amino acid position, A435S mutation at amino acid position 435, W436R mutation at amino acid position 436, G476S mutation at amino acid position 476, V483A mutation at amino acid position 483, N354D/D364Y at amino acid positions 354 and 364 A mutant virus in which a mutation has occurred, but is not limited thereto.
  • the monoclonal antibody of the present invention has the effect of reducing the clinical severity of SARS-CoV-2 virus.
  • the monoclonal antibody RD3 of the present invention when the monoclonal antibody RD3 of the present invention is in the form of IgG4, it is more effective in reducing the clinical severity of SARS-CoV-2 virus infection than in the form of IgG1.
  • the present invention provides a pharmaceutical composition for preventing or treating SARS-CoV infection comprising an antibody or antigen-binding fragment thereof that specifically binds to the above-described SARS-CoV-2 S protein.
  • a pharmaceutical composition for preventing or treating SARS-CoV infection comprising an antibody or antigen-binding fragment thereof that specifically binds to the above-described SARS-CoV-2 S protein.
  • the pharmaceutical composition of the present invention uses the above-described anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention as an active ingredient, the content common between the two is provided in order to avoid excessive complexity of the present specification. , the description is omitted.
  • Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.
  • a lubricant e.g., a talc, a kaolin, a kaolin, a kaolin, a kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, a talct, a talct, a talct, a talct, a sorbitol, mannitol, mannitol
  • composition of the present invention may be administered orally or parenterally, for example, intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intrasternal injection, local administration, intranasal administration, intrapulmonary administration and rectal administration.
  • intravenous injection subcutaneous injection, intramuscular injection, intraperitoneal injection, intrasternal injection, local administration, intranasal administration, intrapulmonary administration and rectal administration.
  • a suitable dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration mode, age, weight, sex, pathological condition, food, administration time, administration route, excretion rate and reaction sensitivity of the patient, An ordinarily skilled physician can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
  • the daily dose of the pharmaceutical composition of the present invention is 0.0001-100 mg/kg.
  • pharmaceutically effective amount refers to an amount sufficient to prevent or treat the above-described diseases.
  • prevention refers to the prevention or protective treatment of a disease or disease state.
  • treatment refers to reduction, suppression, sedation or eradication of a disease state.
  • the pharmaceutical composition of the present invention is prepared in a unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily carried out by a person of ordinary skill in the art to which the present invention pertains. or may be prepared by incorporation into a multi-dose container.
  • the formulation may be in the form of a solution, suspension or emulsion in oil or aqueous medium, or may be in the form of an extract, powder, suppository, powder, granule, tablet, or capsule, and may additionally include a dispersant or stabilizer.
  • the present invention provides the above-described i) an anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof and ii) a polypeptide complex in which an additional polypeptide is linked; And it provides a pharmaceutical composition for preventing or treating SARS-CoV-2 infection, comprising a pharmaceutically acceptable carrier.
  • the additional polypeptide may be an anti-SARS-CoV-2 antibody or antigen-binding fragment thereof, or a target-binding non-antibody polypeptide that specifically binds to SARS-CoV-2. have.
  • the anti-SASRS-CoV-2 antibody or antigen-binding fragment thereof may be the aforementioned antibody or antigen-binding fragment thereof of the present invention.
  • the polypeptide complex may include two or more antibodies or antigen-binding fragments thereof among the above-described antibodies or antigen-binding fragments thereof of the present invention, but is not limited thereto.
  • composition of the present invention uses the above-described polypeptide complex of the present invention as an active ingredient, common content between the two is omitted in order to avoid excessive complexity of the present specification.
  • the present invention provides a composition for detecting SARS-CoV-2 virus comprising an antibody or antigen-binding fragment thereof that specifically binds to the above-described SARS-CoV-2 S protein, or SARS-CoV -2 To provide a composition for diagnosing infectious disease (COVID-19).
  • the present invention provides a composition for detecting SARS-CoV-2 virus comprising an antibody or antigen-binding fragment thereof that specifically binds to the above-described SARS-CoV-2 S protein, or SARS-CoV -2 To provide a composition for diagnosing infectious disease (COVID-19).
  • the antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 S protein of the present invention as described above specifically binds not only to SARS-CoV-2 but also to the S protein of SARS-CoV. It can also be usefully used for the prevention or treatment of
  • composition for detection or diagnosis of the present invention includes the above-described anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention as a component, and detects the same virus as the pharmaceutical composition of the present invention, Since the same disease is diagnosed, descriptions of common content between the two are omitted in order to avoid excessive complexity of the present specification.
  • the present invention is for detecting SARS-CoV-2 virus comprising the composition for detecting SARS-CoV-2 virus or the composition for diagnosing SARS-CoV-2 infection (COVID-19)
  • a kit or a kit for diagnosing SARS-CoV-2 infection (COVID-19) infection is provided.
  • the present invention provides a kit for detecting SARS-CoV virus, or a kit for diagnosing SARS-CoV infection, comprising the composition for detecting SARS-CoV virus or the composition for diagnosing SARS-CoV infection do.
  • composition or kit described above includes the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention, it can be basically prepared to be suitable for various immunoassays or immunostaining.
  • the immunoassay or immunostaining may include radioimmunoassay, radioimmunoprecipitation, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), capture-ELISA, inhibition or competition assay, sandwich assay, flow cytometry, immunofluorescence staining and immunoaffinity tablets, but are not limited thereto.
  • the immunoassay or immunostaining method is described in Enzyme Immunoassay , ET Maggio, ed., CRC Press, Boca Raton, Florida, 1980; Gaastra, W., Enzyme-linked immunosorbent assay (ELISA), in Methods in Molecular Biology , Vol. 1, Walker, JM ed., Humana Press, NJ, 1984; and Ed Harlow and David Lane, Using Antibodies: A Laboratory Manual , Cold Spring Harbor Laboratory Press, 1999, which is incorporated herein by reference.
  • an antibody labeled with a radioisotope (eg, C 14 , I 125 , P 32 and S 35 ) converts the SARS-CoV-2 S protein. can be used to detect.
  • a specific embodiment of the present invention comprises the steps of (i) coating a sample to be analyzed on the surface of a solid substrate; (ii) reacting the sample with an antibody that specifically binds to the SARS-CoV-2 S protein of the present invention as a primary antibody; (iii) reacting the product of step (ii) with an enzyme-conjugated secondary antibody; and (iv) measuring the activity of the enzyme.
  • Suitable as the solid substrate are hydrocarbon polymers (eg, polystyrene and polypropylene), glass, metal or gel, most specifically microtiter plates.
  • the enzyme bound to the secondary antibody includes, but is not limited to, an enzyme catalyzing a color reaction, a fluorescence reaction, a luminescence reaction, or an infrared reaction, for example, alkaline phosphatase, beta-galactosidase, hose Radish peroxidase, luciferase and cytochrome P450 .
  • alkaline phosphatase When alkaline phosphatase is used as the enzyme binding to the secondary antibody, bromochloroindolyl phosphate (BCIP), nitro blue tetrazolium (NBT), naphthol-AS-B1-phosphate (naphthol-AS) as substrates -B1-phosphate) and ECF (enhanced chemifluorescence) are used, and when horse radish peroxidase is used, chloronaphthol, aminoethylcarbazole, diaminobenzidine, D-luciferin, lucigenin (bis -N-methylacridinium nitrate), resorufin benzyl ether, luminol, Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine), HYR (p-phenylenediamine-HCl and pyrocatechol), TMB (tetramethylbenzidine), ABTS (2
  • a specific embodiment of the present invention comprises (i) coating an antibody that specifically binds to SARS-CoV-2 S as a capturing antibody on the surface of a solid substrate. step; (ii) reacting the capture antibody with the sample; (iii) reacting the result of step (ii) with a detecting antibody to which a label generating signal is bound; and (iv) measuring a signal generated from the label.
  • the detection antibody of the present invention has a label that generates a detectable signal.
  • the label may include chemicals (eg, biotin), enzymes (alkaline phosphatase, beta-galactosidase, horse radish peroxidase and cytochrome P 450 ), radioactive substances (eg, C 14 , I 125 , P ). 32 and S 35 ), fluorescent materials (eg, fluorescein), luminescent materials, chemiluminescent materials, and fluorescence resonance energy transfer (FRET).
  • chemicals eg, biotin
  • enzymes alkaline phosphatase, beta-galactosidase, horse radish peroxidase and cytochrome P 450
  • radioactive substances eg, C 14 , I 125 , P .
  • 32 and S 35 eg, fluorescent materials (eg, fluorescein), luminescent materials, chemiluminescent materials, and fluorescence resonance energy transfer (FRET).
  • the final enzyme activity measurement or signal measurement may be performed according to various methods known in the art. If biotin is used as a label, the signal can be easily detected with streptavidin and with luciferin when luciferase is used.
  • capture antibody and detection antibody two types of antibodies or antigen-binding fragments binding to different epitopes among clones of the anti-SARS-CoV-2 protein S antibody or antigen-binding fragment of the present invention may be used.
  • Samples that can be applied to the kit of the present invention include, but are not limited to, cells, tissues or tissue-derived extracts, lysates or purified products, blood, plasma, serum, lymph, or ascites.
  • the antibodies of the present invention can be used for in vivo or in vitro imaging.
  • the present invention provides a composition for imaging comprising the above-described antibody of the present invention and a label-bound conjugate that generates a detectable signal bound to the antibody.
  • the label generating the detectable signal is a T1 contrast material (eg, a Gd chelate compound), a T2 contrast material (eg, a superparamagnetic material (eg, magnetite, Fe 3 O 4 , ⁇ -Fe 2 O 3 , manganese ferrite, cobalt) ferrite and nickel ferrite)), radioactive isotopes (eg, 11 C, 15 O, 13 N, P 32 , S 35 , 44 Sc, 45 Ti, 118 I, 136 La, 198 Tl, 200 Tl, 205 Bi and 206 Bi), fluorescent substances (fluorescein, phycoerythrin, rhodamine, lissamine, and Cy3 and Cy5), chemiluminescent groups, magnetic particles, mass-labeled or electron dense particles.
  • the present invention is not limited thereto.
  • the anti-SARS-CoV-2 S protein antibody or antigen-binding fragment thereof of the present invention specifically binds to the S protein, which plays an important role in the penetration of SARS-CoV-2 into host cells, thereby causing SARS-CoV-2 infection. Since it can inhibit the disease, it can be usefully used as a therapeutic agent for COVID-19, and can be usefully used as a diagnostic agent and diagnostic kit for COVID-19.
  • S1, S2, and RBD proteins which are proteins constituting the SARS-CoV-2 spike.
  • S1 is a SDS-PAGE analysis result of S1, S2, and RBD protein antigens of the purchased SARS-CoV-2 spike protein.
  • FIG. 3 is a diagram showing the results of scFv and phage ELISA binding to RBD for the selection of RBD antigen-specific human antibodies against SARS-CoV-2 virus.
  • 5 is a diagram showing the SDS-PAGE results of 5 selected SARS-CoV-2 RBD-specific IgG antibodies.
  • FIG. 6 is a diagram showing the results of analysis of the reactivity of the five SARS-CoV-2 RBD-specific IgG screening antibodies to the three SARS-CoV-2 antigens (RBD, Spike, S1) using ELISA.
  • FIG. 7 is a diagram showing the results of cross-reactivity analysis of five SARS-CoV-2 RBD-specific IgG selection antibodies against the RBD antigens of SARS-CoV-2 and SARS-CoV virus using ELISA.
  • FIG. 8 is a diagram showing the results of affinity analysis of five SARS-CoV-2 RBD-specific IgG screening antibodies to the SARS-CoV-2 S1 antigen.
  • FIG. 9 is a diagram showing the results of affinity analysis of 5 types of SARS-CoV-2 RBD-specific IgG selection antibodies to the SARS-CoV-2 RBD antigen.
  • FIG. 10 is a diagram showing the results of SDS-PAGE analysis for confirming the molecular weight and purity of the purchased 9 RBD mutant antigens of SARS-CoV-2.
  • 11 is a diagram showing the results of reactivity analysis of 9 types of RBD mutants of SARS-CoV-2 and 5 types of SARS-CoV-2 RBD-specific selection antibodies.
  • FIG. 12 shows a schematic diagram of a direct interaction analysis method between hACE2 and SARS-CoV-2 RBD protein.
  • FIG. 13 is a diagram showing changes in measured values of direct interaction with SARS-CoV-2 RBD protein according to the concentration of hACE2.
  • FIG. 14 is a schematic diagram showing the direct interaction inhibitory ability analysis of hACE2 and SARS-CoV-2 RBD protein by the antibody.
  • 15 is a diagram illustrating the direct interaction inhibition ability and IC 50 measurement results between hACE2 and SARS-CoV-2 RBD protein by 5 types of IgG selection antibodies.
  • SPR surface plasmon resonance
  • SPR surface plasmon resonance
  • FIG. 18 is a diagram showing the neutralizing activity of the monoclonal antibody RD3 of the present invention against SARS-CoV-2 pseudovirus infection and its IC 50 .
  • FIG. 19 and 20 are diagrams showing changes in body weight (FIG. 19) and clinical severity (FIG. 20) when the monoclonal antibody RD3 of the present invention was administered to mice infected with wild-type SARS-CoV-2 virus.
  • % used to indicate the concentration of a specific substance is (weight/weight) % for solid/solid, (weight/volume) % for solid/liquid, and Liquid/liquid is (vol/vol) %.
  • the present inventors purchased the SARS-CoV-2 spike full-length protein and its constituent proteins, S1 and RBD protein antigens, from Sino Biological.
  • the composition of the S1 and RBD proteins of the spike protein is shown in FIG. 1 . Purity and molecular weight of the purchased protein was confirmed through SDS-PAGE (FIG. 2).
  • Example 2 Selection of RBD antigen-specific human antibody of SARS-CoV-2 virus using phage display technique
  • phage display technique After conjugation of a certain amount of SARS-CoV-2 RBD antigen with an epoxy-conjugated Dynabead (Invitrogen, USA), a phage display technique was used to select RBD-specific human antibodies. After 5 rounds of bio-panning, the titer and enrichment degree for each order of the binding antibody clones were confirmed through titration. Then, through individual phage ELISA, human antibody clones with excellent reactivity to the RBD antigen and specific antigen are selected, DNA is secured through miniprep, and 10 types of RBD-specific human antibodies with different CDR sequences are analyzed through nucleotide sequencing. secured. The results of phage ELISA are shown in FIG. 3 .
  • the selection antibody was purified by affinity column chromatography using protein A sepharose beads.
  • the results of comparative analysis of the yield after mass production and final purification of the RBD-specific IgG antibody of the present invention are shown in FIG. 4 .
  • the present inventors loaded the selected SARS-CoV-2 RBD-specific 5 types of antibodies in equal amounts on polyacrylamide gel, proceeded with SDS-PAGE, and finally all 5 types of antibodies had a purity of 95% or more through Coomassie Brilliant Blue staining. It was confirmed, and the molecular weight size was also confirmed that the heavy chain and light chain of the antibody were 50 kDa and 25 kDa, respectively (FIG. 5).
  • the present inventors purchased SARS-CoV-2 and SARS-CoV RBD antigens to confirm the reactivity to SARS-CoV RBD antigens as well as SARS-CoV-2 RBD antigens of the five selected SARS-CoV-2 specific selection antibodies. After coating 0.1 ⁇ g on a 96-well high binding plate (Corning, USA), ELISA was performed for each antibody. The results are shown in FIG. 7 .
  • the present inventors added the purchased SARS-CoV-2 RBD and S1 to a 96-well high binding plate (Corning, USA), respectively. After binding, the affinity (Kd value) was calculated by measuring the absorbance (450 nm) while increasing the concentration of the selection antibody. The results are shown in FIGS. 8 and 9 .
  • FIG. 8 is a diagram showing the results of affinity analysis of five RBD-specific selection antibodies to the SARS-CoV-2 S1 antigen.
  • 9 is a diagram showing the results of affinity analysis of five RBD-specific selection antibodies to the SARS-CoV-2 RBD antigen.
  • the Kd value for the S1 antigen was confirmed to be low in the order of RB4, RG6, RD3, RD10, RB6, and the Kd value for the RBD antigen was RB4, RD3, RG6, RD10, The lowest Kd value was confirmed in the order of RB6.
  • the Kd value of the four antibodies against the S1 antigen of RB4, RD3, RD10, and RG6 was 10 -10 M, and all the five antibodies against the RBD antigen had the Kd value of 10 -10 M concentration. was confirmed, and it was finally confirmed that the selection antibody had high affinity for each antigen.
  • the present inventors have identified antigens for 9 representative RBD variants (V431A, F342L, V367F, R408I, A435S, W436R, G476S, V483A, N354D/D364Y) worldwide classified by country. was purchased and secured from Sino Biological. Thereafter, the purity and molecular weight of each antigen were confirmed through SDS-PAGE, and as a result, the size of the RBD variant of about 30 kDa and a purity of 90% or more were finally confirmed ( FIG. 10 ).
  • Example 5 Evaluation of direct interaction inhibitory ability of hACE2 and SARS-CoV-2 RBD protein (functional analysis for deriving leading substances)
  • the present inventors performed ELISA using the purified protein to analyze the neutralizing ability of the antibody inhibiting the protein-protein interaction between the hACE2 receptor and the SARS-CoV-2 spike protein. For this, the neutralizing ability was analyzed using the Spike RBD (SARS-CoV-2):ACE2 inhibitor screening assay kit (Cat. No. 79931) supplied by BPS Bioscience.
  • SARS-CoV-2 RBD protein (Fc-tagged) was coated on a 96-well plate provided in the assay kit and incubated with a ligand human ACE2 (His-tagged; hACE2-His). Then, the binding capacity between RBD domian-ACE2 was measured by adding anti-His-HRP and HRP substrate and measuring chemiluminescence using an ELISA reader.
  • FIG. 12 A schematic diagram of a direct interaction analysis method between hACE2-His and SARS-CoV-2 RBD protein is shown in FIG. 12 . The results of the test method are shown in FIG. 13 .
  • the binding inhibitory ability between SARS-CoV-2 RBD and hACE2 by the selection antibody was measured by an established direct interaction assay method.
  • SARS-CoV-2 RBD protein (Fc-tagged) is coated on a 96-well plate provided in the assay kit, and the ligand hACE2-His is applied alone or with a selection antibody (0.016, 0.08, 0.4, 2, 10, 50 nM) were incubated together. Then, the anti-His-HRP and HRP substrate was put, and the binding inhibitory ability between SARS-CoV-2 RBD and hACE2 by the presence or absence of antibody was measured by measuring chemiluminescence using an ELISA reader. A schematic diagram of this test method is shown in FIG. 14 . The results are shown in FIG. 15 .
  • RB4 was 0.8412 nM
  • RB6 was 1.950 nM
  • RD3 was 1.315 nM
  • RD10 was 1.965 nM
  • RG6 was 84.02 nM.
  • four antibodies, RB4, RB6, RD3, and RD10 could effectively inhibit the binding between SARS-CoV-2 RBD and hACE2 even at very low concentrations.
  • the binding kinetics of antibodies (RD3 and RB6) to SARS-CoV-2 RBD were run with 10 mM HEPES pH 7.4, 700 mM NaCl, 2 mM CaCl 2 , 1 mM MnCl 2 and 0.005% (v/v) Tween-20. It was used as a buffer and analyzed at 25° C. in an iMSPR-mini instrument (iCLUEBIO, Seongnam, Korea). Recombinant SARS-CoV-2 RBD (wild-type, Alpha, Beta, Gamma, Delta or Kappa) was covalently immobilized on the surface of a COOH-Au chip (iCLUEBIO) up to 500 response units via standard amine coupling.
  • iCLUEBIO COOH-Au chip
  • Monoclonal antibodies (8 nM, 16 nM, 32 nM, 64 nM, and 128 nM) were injected onto the sensor chip surface at a flow rate of 50 ⁇ L/min. Curve fitting and data analysis were performed using iMSPR analysis software (Tracedrawer; iCLUEBIO). The results are shown in Table 1 and Table 2 and FIGS. 16 and 17 .
  • Lenti-X TM SARS -CoV-2 Pseudotyped replication-deficient lentiviral particles carrying wild-type or SARS-CoV-2 spike protein carrying B.1 (D614G) and a firefly luciferase reporter gene are Lenti-X TM SARS -CoV-2 was prepared using packaging mix (Takara Bio, Kusatsu, Japan). Briefly, Lenti-X SARS-CoV-2 packaging mix was transiently transfected into Expi293F cells using ExpiFectamine TM 293 reagent. After incubation for 72 hours, the supernatant containing pseudovirus was collected and briefly centrifuged (500xg for 10 min) to remove cell debris. Virus titration was determined using a Lenti-X GoStix TM Plus (Takara Bio) according to the manufacturer's instructions.
  • MMV malony murine leukemia virus
  • B.1.1.7 alpha
  • B.1.617.2 delta
  • B.1.617 kappa
  • Variants and genes expressing the firefly luciferase reporter gene were obtained from eEnzyme (Gaithersburg, MD, USA).
  • Firefly luciferase reporter gene expression was measured using ONE-Glo TM luciferase substrate (Promega; Madison, WI, USA). Briefly, culture medium was removed and incubated with 100 ⁇ l of ONE-Glo TM substrate. After 5 min, 70 ⁇ l of the supernatant was transferred to a white flat bottom 96 well assay plate (Corning; Lowell, MA, USA) and the luminescence signal was measured with a Synergy H1 microplate reader. The resulting relative luminescent units were normalized to those derived from cells infected with SARS-CoV-2 pseudovirus in the absence of antibody. IC 50 was determined using 4-parameter nonlinear regression (GraphPad Prism 8).
  • Example 9 In vivo infection and clinical monitoring
  • the group administered with the RD3 monoclonal antibody in the form of IgG4 did not reduce the weight relatively compared to the group administered with PBS, thereby reducing the clinical severity.
  • the RD3 (IgG4) administration group showed relatively low clinical severity compared to the PBS or RD3 (IgG1) administration group. From the above results, it can be seen that the RD3 monoclonal antibody of the present invention has better efficacy in the form of IgG4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps anti-protéine S de SARS-CoV-2 ou un fragment de liaison à l'antigène de celui-ci, et ses utilisations thérapeutiques et diagnostiques. L'anticorps anti-protéine S de SARS-CoV-2 ou un fragment de liaison à l'antigène de celui-ci selon la présente invention peut se lier de manière spécifique à la protéine S, qui joue un rôle important dans l'infiltration de SARS-CoV-2 dans des cellules hôtes, pour inhiber l'infection par le SARS-CoV-2, et peut ainsi être utilisé de manière avantageuse en tant qu'agent thérapeutique pour COVID-19 et en tant qu'agent de diagnostic et kit de diagnostic pour COVID-19.
PCT/KR2022/006054 2021-04-27 2022-04-27 Anticorps se liant de manière spécifique à la protéine s de sars-cov-2 ou à un fragment de liaison à l'antigène de celle-ci, et ses utilisations WO2022231320A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/383,595 US20240043508A1 (en) 2021-04-27 2023-10-25 Antibody binding specifically to sars-cov-2 s protein or antigen-binding fragment thereof, bispecific antibody, and uses thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
KR1020210054596A KR20220147766A (ko) 2021-04-27 2021-04-27 SARS-CoV-2 S 단백질에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편, 및 이들의 용도
KR1020210054606A KR20220147769A (ko) 2021-04-27 2021-04-27 SARS-CoV-2 S 단백질에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편, 및 이들의 용도
KR1020210054590A KR20220147765A (ko) 2021-04-27 2021-04-27 SARS-CoV-2 S 단백질에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편, 및 이들의 용도
KR10-2021-0054590 2021-04-27
KR10-2021-0054603 2021-04-27
KR10-2021-0054606 2021-04-27
KR10-2021-0054600 2021-04-27
KR20210054600 2021-04-27
KR20210054603 2021-04-27
KR10-2021-0054596 2021-04-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/006055 Continuation WO2022231321A1 (fr) 2021-04-27 2022-04-27 Composition ou kit de diagnostic comprenant un anticorps spécifique d'un antigène rbd de sars-cov-2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/010843 Continuation WO2023033363A1 (fr) 2021-04-27 2022-07-22 Anticorps bispécifique se liant de manière spécifique au sars-cov-2

Publications (1)

Publication Number Publication Date
WO2022231320A1 true WO2022231320A1 (fr) 2022-11-03

Family

ID=83847117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/006054 WO2022231320A1 (fr) 2021-04-27 2022-04-27 Anticorps se liant de manière spécifique à la protéine s de sars-cov-2 ou à un fragment de liaison à l'antigène de celle-ci, et ses utilisations

Country Status (1)

Country Link
WO (1) WO2022231320A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787501B1 (en) * 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
KR102233689B1 (ko) * 2020-11-26 2021-03-30 재단법인 오송첨단의료산업진흥재단 SARS-CoV-2 스파이크 단백질의 수용체-결합 도메인에 특이적으로 결합하는 항체 및 이의 이용
EP3809137A1 (fr) * 2020-02-19 2021-04-21 Euroimmun Medizinische Labordiagnostika AG Procédés et réactifs pour le diagnostic d'une infection par le sars-cov-2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809137A1 (fr) * 2020-02-19 2021-04-21 Euroimmun Medizinische Labordiagnostika AG Procédés et réactifs pour le diagnostic d'une infection par le sars-cov-2
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
US10787501B1 (en) * 2020-04-02 2020-09-29 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
KR102233689B1 (ko) * 2020-11-26 2021-03-30 재단법인 오송첨단의료산업진흥재단 SARS-CoV-2 스파이크 단백질의 수용체-결합 도메인에 특이적으로 결합하는 항체 및 이의 이용

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIM CHEOLMIN, RYU DONG-KYUN, LEE JIHUN, KIM YOUNG-IL, SEO JI-MIN, KIM YEON-GIL, JEONG JAE-HEE, KIM MINSOO, KIM JONG-IN, KIM PANKYE: "A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein", NATURE COMMUNICATIONS, vol. 12, no. 1, 1 December 2021 (2021-12-01), XP055889424, DOI: 10.1038/s41467-020-20602-5 *

Similar Documents

Publication Publication Date Title
WO2019098682A1 (fr) Anticorps anti-her2 ou fragment de liaison à l'antigène de celui-ci, et récepteur antigénique chimérique le comprenant
WO2020111913A1 (fr) Anticorps anti-4-1bb et son utilisation
WO2019225777A1 (fr) Anticorps anti-ror1 et son utilisation
WO2016137108A1 (fr) Nouvel anticorps se liant à la tfpi et composition le comprenant
WO2019225787A1 (fr) Anticorps anti-b7-h3 et son utilisation
WO2014077648A1 (fr) Anticorps se liant spécifiquement à la protéine l1cam humaine et murine, et son utilisation
WO2019112347A2 (fr) Anticorps ou son fragment de liaison à l'antigène pour reconnaître spécifiquement une malignité de cellule b, récepteur d'antigène chimérique le comprenant, et son utilisation
WO2022039490A1 (fr) Anticorps bispécifiques anti-b7-h4/anti-4-1bb et leurs utilisations
WO2021133036A1 (fr) Anticorps anti-lilrb1 et ses utilisations
WO2020101365A1 (fr) Anticorps anti-c-met présentant une stabilité améliorée ou des fragments de liaison à l'antigène de celui-ci
WO2019078699A2 (fr) Anticorps anti-vista et son utilisation
WO2021101346A1 (fr) Anticorps bispécifiques anti-ror1/anti-4-1bb et leurs utilisations
WO2021010800A1 (fr) Anticorps se liant spécifiquement à la protéine wrs, et son utilisation
WO2022231320A1 (fr) Anticorps se liant de manière spécifique à la protéine s de sars-cov-2 ou à un fragment de liaison à l'antigène de celle-ci, et ses utilisations
WO2022085905A1 (fr) Anticorps se liant spécifiquement à la protéine de spicule du sars-cov-2 et utilisation associée
WO2019216675A1 (fr) Épitope d'antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci
WO2022177392A1 (fr) Anticorps à domaine unique dirigé contre cd47 et son utilisation
WO2023033363A1 (fr) Anticorps bispécifique se liant de manière spécifique au sars-cov-2
WO2018026249A1 (fr) Anticorps dirigé contre le ligand 1 de mort programmée (pd-l1) et son utilisation
WO2020250204A1 (fr) Nouveaux anticorps spécifiques de cthrc1 et leur utilisation
WO2017179862A1 (fr) Anticorps à stabilité améliorée et se liant spécifiquement à her2
WO2022119310A1 (fr) Anticorps se liant spécifiquement à aimp2 et/ou à un agrégat d'aimp2
WO2021251564A1 (fr) Anticorps se liant de manière spécifique à grp94 ou un fragment de liaison à l'antigène de celui-ci, et utilisations associées
WO2017142294A1 (fr) Anticorps anti-egfrviii et utilisation correspondante
WO2022240161A1 (fr) Anticorps anti-gitr et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22796152

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22796152

Country of ref document: EP

Kind code of ref document: A1